Beneficial outcomes with pembrolizumab plus chemotherapy persist with different types of chemotherapy in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer, exploratory analysis of the KEYNOTE-355 trial suggests.
The PENELOPE-B investigators have found no invasive disease-free survival benefit with a 1-year course of palbociclib alongside endocrine therapy for hormone receptor-positive breast cancer patients who did not achieve a complete pathologic response to neoadjuvant chemotherapy.
A prognostic tool that integrates clinicopathologic and genomic data provides more information on distant recurrence risk than either feature alone, and can estimate absolute chemotherapy benefit in individual patients with node-negative breast cancer, say researchers.
